Literature DB >> 9632909

Lung inflammatory response in pneumonia.

C Montón1, A Torres.   

Abstract

In normal conditions, alveolar macrophages (AMs) are the main cells that respond to bacteria that reach lower airways. However, if the microbial inoculum is too high or too virulent to be stopped by AM alone, these cells recruit polymorphonuclear neutrophils (PMN) into the alveoli from the vascular compartment. Cytokines, such as tumour necrosis factor-alpha (TNF-alpha), interleukin-1-beta (IL-beta), interleukin-6 (IL-6), and interleukin-8 (IL-8), secreted by the AM are able to attract PMN enhanced for phagocytosis, ready to destroy the invading pathogens. However, excessive cytokine production has deleterious effects, with a systemic inflammatory response (sepsis) that can lead to multiorganic failure and death. Other cytokines, such as interleukin-10 (IL-10) balance this response, attenuating several inflammatory mechanisms. The inflammatory lung response in pneumonia has been well studied in animals, and more recently in humans, using bronchoalveolar lavage to measure some inflammatory mediators (TNF-alpha, IL-1 beta, IL-6, IL-8). From these studies, it seems that: 1) the inflammatory response to pneumonia is compartmentalized for most cytokines (in contrast to adult respiratory distress syndrome (ARDS)), except for IL-6 which is a general marker of inflammation. On the other hand, C-reactive-protein is an acute-phase protein synthesized by the liver through the stimulus of IL-6 that may also be an easy-to-measure marker of inflammation that is directly related to IL-6; 2) some of these cytokines may be useful as prognostic indices; 3) there is no clear relationship between the local lung bacterial burden and the intensity of the inflammatory response; and 4) the administration of granulocyte colony-stimulating factor (G-CSF) is a promising therapeutic approach that is still under clinical investigation. In the future, it is probable that the therapeutic goal in severe pneumonia will be to find the exact point at which inflammation is beneficial but not deleterious. The measurement of the inflammatory response may serve for this purpose.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9632909

Source DB:  PubMed          Journal:  Monaldi Arch Chest Dis        ISSN: 1122-0643


  26 in total

1.  Acute lung injury: apoptosis in effector and target cells of the upper and lower airway compartment.

Authors:  B Roth Z'graggen; J Tornic; B Müller-Edenborn; L Reyes; C Booy; B Beck-Schimmer
Journal:  Clin Exp Immunol       Date:  2010-05-07       Impact factor: 4.330

Review 2.  Pneumonia research to reduce childhood mortality in the developing world.

Authors:  J Anthony G Scott; W Abdullah Brooks; J S Malik Peiris; Douglas Holtzman; E Kim Mulholland
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

3.  Hypoxia aggravates lipopolysaccharide-induced lung injury.

Authors:  D Vuichard; M T Ganter; R C Schimmer; D Suter; C Booy; L Reyes; T Pasch; B Beck-Schimmer
Journal:  Clin Exp Immunol       Date:  2005-08       Impact factor: 4.330

Review 4.  Hidden risks for pneumonia in Malawi.

Authors:  D G Fullerton; S B Gordon
Journal:  Malawi Med J       Date:  2003-06       Impact factor: 0.875

Review 5.  Advanced Age Alters Monocyte and Macrophage Responses.

Authors:  Joslyn M Albright; Robert C Dunn; Jill A Shults; Devin M Boe; Majid Afshar; Elizabeth J Kovacs
Journal:  Antioxid Redox Signal       Date:  2016-08-03       Impact factor: 8.401

6.  Fas-activated serine/threonine phosphoprotein promotes immune-mediated pulmonary inflammation.

Authors:  Maria Simarro; Giorgio Giannattasio; Miguel A De la Fuente; Charaf Benarafa; Kulandayan K Subramanian; Rumey Ishizawar; Barbara Balestrieri; Emma M Andersson; Hongbo R Luo; Antonio Orduña; Joshua Boyce; Paul Anderson
Journal:  J Immunol       Date:  2010-04-02       Impact factor: 5.422

7.  Cardiorespiratory Fitness is Associated with Reduced Risk of Respiratory Diseases in Middle-Aged Caucasian Men: A Long-Term Prospective Cohort Study.

Authors:  Setor K Kunutsor; Tanjaniina Laukkanen; Jari A Laukkanen
Journal:  Lung       Date:  2017-07-11       Impact factor: 2.584

8.  Post-treatment change in Mycobacterium tuberculosis antigen-stimulated tumor necrosis factor-alpha release in patients with active tuberculosis.

Authors:  Chang Ho Kim; Seung Soo Yoo; Shin Yup Lee; Seung Ick Cha; Jae Yong Park; Jaehee Lee
Journal:  J Thorac Dis       Date:  2015-05       Impact factor: 2.895

9.  Sauna bathing reduces the risk of respiratory diseases: a long-term prospective cohort study.

Authors:  Setor Kwadzo Kunutsor; Tanjaniina Laukkanen; Jari Antero Laukkanen
Journal:  Eur J Epidemiol       Date:  2017-09-13       Impact factor: 8.082

10.  Isoflurane attenuates lipopolysaccharide-induced acute lung injury by inhibiting ROS-mediated NLRP3 inflammasome activation.

Authors:  Ning Yin; Zhendan Peng; Bin Li; Jiangyan Xia; Zhen Wang; Jing Yuan; Lei Fang; Xinjiang Lu
Journal:  Am J Transl Res       Date:  2016-05-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.